Multiplex Assay for Activated p300CBP in Circulating Prostate Tumor Cells Oncotarget

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=KhAL2ODhRcs

Oncotarget published this research paper on July 20, 2023 in Volume 14, entitled, “Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells” by researchers from the Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI; Department of Hematology/Oncology, University of Wisconsin, Madison, WI; Biomolecular Chemistry, University of Wisconsin, Madison, WI; Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI. ‪@uwmadison‬ • #cancer #prostatecancer #tumors #cells #cancerresearch #research #researchpaper #openaccess #openscience #peerreview #journal #publication #meded #publishing • DOI - https://doi.org/10.18632/oncotarget.2... • Correspondence to - David F. Jarrard - [email protected] • Abstract • Reduced SIRT2 deacetylation and increased p300 acetylation activity leads to a concerted mechanism of hyperacetylation at specific histone lysine sites (H3K9, H3K14, and H3K18) in castration-resistant prostate cancer (CRPC). We examined whether circulating tumor cells (CTCs) identify patients with altered p300/CBP acetylation. CTCs were isolated from 13 advanced PC patients using Exclusion-based Sample Preparation (ESP) technology. Bound cells underwent immunofluorescent staining for histone modifying enzymes (HMEs) of interest and image capture with NIS-Elements software. Using the cBioPortal PCF/SU2C dataset, the response of CRPC to androgen receptor signaling inhibitors (ARSI) was analyzed in 50 subjects. Staining optimization and specificity revealed clear expression of acetyl-p300, acetyl-H3K18, and SIRT2 on CTCs (CK positive, CD45 negative cells). Exposure to A-485, a selective p300/CBP catalytic inhibitor, reduced p300 and H3K18 acetylation. In CRPC patients, a-p300 strongly correlated with its target acetylated H3k18 (Pearson’s R = 0.61), and SIRT2 expression showed robust negative correlation with a-H3k18 (R = −0.60). A subgroup of CRPC patients (6/11; 55%) demonstrated consistent upregulation of acetylation based on these markers. To examine the clinical impact of upregulation of the CBP/p300 axis, CRPC patients with reduced deacetylase SIRT2 expression demonstrate shorter response times to ARSI therapy (5.9 vs. 12 mo; p = 0.03). A subset of CRPC patients demonstrate increased p300/CBP activity based on a novel CTC biomarker assay. With further development, this biomarker suite may be used to identify candidates for CBP/p300 acetylation inhibitors in clinical development. • Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/deta... • Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ • Keywords - prostate cancer, circulating tumor cells, p300/CBP • About Oncotarget • Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. • To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: • SoundCloud - / oncotarget • Facebook - / oncotarget • Twitter - / oncotarget • Instagram - / oncotargetjrnl • YouTube - / @oncotargetjournal • LinkedIn - / oncotarget • Pinterest - / oncotarget • Reddit - / oncotarget • Media Contact • [email protected] • 18009220957

#############################

New on site